You are here: Home » 2021 » April » Archives for 19th

CoreCard® Business Update: CoreCard partners with Al Ansari Exchange to offer multi-currency prepaid card processing in the UAE

DUBAI, United Arab Emirates, April 19, 2021 (GLOBE NEWSWIRE) — CoreCard Software, DMCC. (a subsidiary of Intelligent Systems Corporation [NYSE American: INS]), the leading international provider of innovative prepaid and credit technology solutions and processing services to the financial technology and services market, announced today a partnership with Al Ansari Exchange, the UAE–based foreign exchange and worldwide money transfer company.

Under this partnership CoreCard is providing prepaid card processing services for the Al Ansari Exchange Visa Platinum Multi–currency travel card. This card can be used at any merchant worldwide that accepts Visa and can be loaded with any of seventeen different currencies making it the smartest, safest and most convenient way to travel whilst enjoying a wide range of benefits and exclusive offers.

This deployment also showcases CoreCard's ability to host its processing services in the cloud which allowed reduced deployment times whilst achieving the highest standards of resilience and the ability to easily scale to match a fast–growing business.

Mohammad Bitar, Deputy Chief Executive Officer, Al Ansari Exchange, said: "Al Ansari Exchange puts great efforts into providing world–class services to its customers using the most advanced technologies and innovative solutions. We are pleased to collaborate with a modern platform such as CoreCard and integrate their technology into our systems to further enhance our customers' experience when using the Al Ansari Exchange Travel Card."

Lee Blair, General Manager for CoreCard in Dubai said, "This is a great day for the new CoreCard Dubai office. We are thrilled to bring CoreCard's market leading platform and processing capabilities into the region and are proud to be working with Al Ansari Exchange to provide such an exciting product to their customers."

About CoreCard

CoreCard Software, a leading provider of card management systems and processing services, offers an array of account management solutions to support the complex requirements of the evolving global financial services industry. CoreCard software solutions provide the market's most feature–rich and flexible platform for processing and managing a full range of card products including prepaid/stored–value, multi–currency wallets, virtual card issuing, instant financing, small loans, point of sale loans, fleet, credit, debit, commercial, government, healthcare and private–label cards as well as accounts receivable and loans. CoreCard is headquartered in Norcross, GA with additional offices in India, the United Arab Emirates and Romania. CoreCard is a subsidiary of Intelligent Systems Corporation [NYSE AMERICAN: INS].

For more information, email solutions@corecard.com, or visit www.corecard.com

About Al Ansari Exchange

Al Ansari Exchange, a leading exchange company in the UAE with the largest branch network, was founded in 1996. Its first branch started as an offshoot of a flourishing general trading business by the Al Ansari family, established primarily to meet the foreign exchange and remittance needs of the Al Ansari family's trading partners and customers.

The company has expanded to over 190 branches nationwide, making it the largest and most popular exchange company in the UAE today. It employs over 2,500 multilingual staff who serve more than 2.5 million customers every month. It is one of the first exchange houses in the country to have integrated innovation and digital technology into its systems and platforms. Its efforts culminated with the launch of Al Ansari Exchange Mobile App in 2018. Currently, the App is the highest–rated app among the exchange houses in the UAE on Google Play and the Apple Store with over one million downloads to date and more than 200,000 active users monthly.

For more information, please visit www.alansariexchange.com


GLOBENEWSWIRE (Distribution ID 8219366)

Zoom Announces $100 Million Zoom Apps Fund

SAN JOSE, Calif., April 19, 2021 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM) today announced the Zoom Apps Fund, a new $100 million venture fund created to stimulate growth of Zoom's ecosystem of Zoom Apps, integrations, developer platform, and hardware. Portfolio companies will receive initial investments between $250,000 and $2.5 million to build solutions that will become core to how Zoom customers meet, communicate, and collaborate. Zoom Apps, announced at Zoomtopia 2020, are leading applications that will bring productivity and engaging experiences directly into the Zoom platform.

Dozens of Zoom Apps are currently in development and are an important component in building the future of video communications. The Zoom Apps Fund will invest in developer partners with viable products and early market traction that will provide valuable and engaging experiences to our customers.

"I founded Zoom in 2011, nearly ten years ago. Without the support of early investors, Zoom would not be what it is today," said Eric S. Yuan, Founder and CEO of Zoom. "What I've learned over the past year is that we need to keep meetings productive and fun. My hope is that the Zoom Apps Fund will help our customers meet happier and collaborate even more seamlessly, and at the same time help entrepreneurs build new businesses as our platform evolves."

To learn more about the Zoom Apps Fund visit zoom.com/fund and read our recent blog post.

About Zoom
Zoom is for you. We help you express ideas, connect to others, and build toward a future limited only by your imagination. Our frictionless communications platform is the only one that started with video as its foundation, and we have set the standard for innovation ever since. That is why we are an intuitive, scalable, and secure choice for individuals, small businesses, and large enterprises alike. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Visit zoom.com and follow @zoom.

Zoom Press Contact
Colleen Rodriguez
Global PR Lead
press@zoom.us


GLOBENEWSWIRE (Distribution ID 8218984)

NeoTX Announces FDA Clearance of IND for Phase 2 Clinical Trial of Naptumomab Estafenatox (NAP), its lead Tumor Targeted Superantigen Candidate

REHOVOT, Israel, April 19, 2021 (GLOBE NEWSWIRE) — NeoTX Therapeutics (NeoTX), a clinical–stage immuno–oncology company, announced today that it received clearance from the U.S. Food and Drug Administration (FDA) for the Company's Investigational New Drug (IND) application for naptumomab estafenatox (NAP). NeoTX is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. NAP, the company's lead TTS molecule, binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells. NAP has demonstrated preliminary safety and anti–tumor activity in early–stage clinical trials in solid tumors.

"This FDA clearance is an exciting milestone for NeoTX," said Asher Nathan, Ph.D., chief executive officer of NeoTX. "Preclinical and preliminary clinical studies have demonstrated that NAP has potential in combination with other treatment modalities. Non–small cell lung cancer is one of the deadliest cancers, and we are looking forward to assessing NAP in the clinic in combination with chemotherapy as a potential new treatment option after failure of current standards of care."

The Phase 2a open label trial will evaluate NAP in combination with docetaxel in 35 patients with checkpoint inhibitor pretreated, advanced or metastatic non–small cell lung cancer. The primary endpoint is objective response rate as measured by RECIST 1.1 criteria. The trial will also evaluate safety, duration of response, progression free survival, overall survival, pharmacokinetics and pharmacodynamics.

About NeoTX
NeoTX is a clinical–stage immuno–oncology company which is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an effective response. The company's lead TTS molecule, naptumomab estafenatox (NAP) is currently in clinical development for advanced solid tumors. For more information, please visit www.neotx.com.

Media Contact:
Cait Williamson, Ph.D.
LifeSci Communications
(646) 751–4366
cait@lifescicomms.com


GLOBENEWSWIRE (Distribution ID 8218939)

Nyxoah Announces Submission of Draft Registration Statement For Proposed Public Listing in the United States

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Announces Submission of Draft Registration Statement For Proposed Public Listing in the United States

Mont–Saint–Guibert, Belgium "" 19 April 2021 "" Nyxoah SA (Euronext Brussels: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that it has confidentially submitted a draft Registration Statement on Form F–1 to the Securities and Exchange Commission (the “SEC”) relating to the proposed public offering of its ordinary shares in the United States. The number of ordinary shares to be offered and the price for the proposed offering have not yet been determined. The public offering is expected to take place after the SEC completes its review process, subject to market and other conditions.

This announcement is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, as amended (the “Securities Act”).

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities, if at all, will be made in accordance with the registration requirements of the Securities Act.

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014).

Contacts:
Nyxoah
Fabian Suarez, Chief Financial Officer
fabian.suarez@nyxoah.com
+32 10 22 24 55

Gilmartin Group
Vivian Cervantes
vivian.cervantes@gilmartinir.com

Attachment


GLOBENEWSWIRE (Distribution ID 1000479118)